Virologic insights from the phase 3 REDPINE trial: remdesivir in renally impaired and immunocompromised patients with COVID-19
Open Access
- 5 August 2026
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 70 (8) , e0191225
Abstract
Remdesivir inhibits the SARS-CoV-2 RNA-dependent polymerase (Nsp12). Here, we present virology analyses from the Phase 3 REDPINE trial in participants with impaired kidney function hospitalized for COVID-19 and treated with remdesivir or placebo for 5 days. Out of 243 participants enrolled and treated in the study, 42 participants had solid organ transplantation (SOT) and received immunosuppressive medication prior to and during the study. Nasopharyngeal swabs were collected at baseline and through Day 29. Virology assessments were performed using SARS-CoV-2 RT-qPCR, next-generation sequencing, and site-directed mutagenesis in a SARS-CoV-2 replicon system. Remdesivir treatment demonstrated significantly greater reductions from baseline in viral load on Day 5 and Day 7 compared with placebo ( P ≤ 0.034). In the remdesivir treatment group, participants with SOT showed significantly smaller viral load reductions from baseline on Days 5, 7, and 14 compared with participants without SOT (all P < 0.05). Mathematical modeling of viral load kinetics in participants with kidney transplants predicted a >13-day faster time to viral load decline by extending the remdesivir treatment duration from 5 days to 10 days. In four participants treated with remdesivir, emergent substitutions in Nsp12 (E136V, M794I, and C799F) with low-level reduced in vitro susceptibility to remdesivir (≤3.4 fold change in half-maximal effective concentration) were observed 9 days after cessation of remdesivir treatment. Three of the four participants had undergone SOT. Overall, remdesivir demonstrated antiviral activity in participants with impaired kidney function, with delayed viral clearance in SOT recipients and rare posttreatment emergence of Nsp12 substitutions that confer low-level reduced susceptibility to remdesivir. CLINICAL TRIALS: This study is registered with ClinicalTrials.gov as NCT04745351 ; EudraCT registration no. 2020-005416-22.Keywords
Funding Information
- Gilead Sciences, Inc. (N/A)
This publication has 34 references indexed in Scilit:
- Extended nirmatrelvir–ritonavir treatment durations for immunocompromised patients with COVID-19 (EPIC-IC): a placebo-controlled, randomised, double-blind, phase 2 trialThe Lancet Infectious Diseases, 2025
- SARS-CoV-2 shedding and evolution in patients who were immunocompromised during the omicron period: a multicentre, prospective analysisThe Lancet Microbe, 2024
- Evaluation of antiviral drugs against newly emerged SARS-CoV-2 Omicron subvariantsAntiviral Research, 2023
- A bacterial artificial chromosome (BAC)-vectored noninfectious replicon of SARS-CoV-2Antiviral Research, 2021
- A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19Nature Communications, 2020
- Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19JAMA, 2020
- Structural Basis for Helicase-Polymerase Coupling in the SARS-CoV-2 Replication-Transcription ComplexCell, 2020
- Remdesivir and SARS-CoV-2: Structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sitesAntiviral Research, 2020
- Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymeraseAntiviral Research, 2019
- Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeysNature, 2016